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Objective: To evaluate the relapse prevention efﬁcacy of lurasidone compared with quetiapine XR (QXR) in
adults patients with schizophrenia.
Method: This double-blind study evaluated the relapse prevention efﬁcacy of 12 months of ﬂexible-dose
treatment with lurasidone (40–160 mg/day) compared with QXR (200–800 mg/day), in outpatients with
an acute exacerbation of chronic schizophrenia who had recently completed a 6-week placebo-controlled
trial of treatment with either lurasidone or QXR. The primary endpoint, time-to-relapse, was analyzed
using a Cox proportional hazards model in this noninferiority trial.
Results: The Kaplan–Meier estimate of the probability of relapse over 12 monthswas 23.7% for subjects receiving
lurasidone vs. 33.6% for QXR. The hazard ratio [95% CI] for probability of relapse was 0.728 [0.410, 1.295]
(log-rank p = 0.280). Since the upper limit of the hazard ratio (1.295) was smaller than the prespeciﬁed
noninferiority margin (1.93), noninferiority of lurasidone compared with QXR was demonstrated in this study.
The probability of hospitalization at 12 months was lower for the lurasidone group compared with the QXR
group (9.8% vs. 23.1%; log-rank p = 0.049). A signiﬁcantly higher proportion of lurasidone subjects achieved
remission at study endpoint compared with the QXR group (61.9% vs. 46.3%; p = 0.043). Discontinuation
rates due to AEs were similar for lurasidone and QXR (7% vs. 5%). Treatment with lurasidone was not associated
with clinically signiﬁcant changes in weight or metabolic parameters.
Conclusions: Twelve months of treatment with lurasidone met noninferiority criteria, and was associated
with higher rates of remission, and reduced risk of hospitalization compared with QXR. No clinically sig-
niﬁcant effects on weight or metabolic parameters were observed during maintenance treatment with
lurasidone.© 2013 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Lurasidone is an atypical antipsychotic agent with potent bind-
ing afﬁnity for D2, 5-HT2A, and 5-HT7 receptors, and moderate afﬁn-
ity for 5-HT1A and α2C receptors (Ishibashi et al., 2010). It has
minimal afﬁnity for histamine H1 and muscarinic M1 receptors,
which are thought to contribute to side effects such as weight
gain, sedation, and cognitive impairment (Ishibashi et al., 2010).ave been previously presented
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ebel).
-NC-ND license.Lurasidone has demonstrated short-term efﬁcacy in the treatment
of acute exacerbation of schizophrenia (Nakamura et al., 2009;
Citrome, 2011; Meltzer et al., 2011). Evidence from both open-
label continuation trials (Citrome, 2011; Stahl et al., in press), and
a randomized, double-blind, long-term trial (Citrome et al., 2012),
suggests that efﬁcacy is maintained over a 12 month treatment
period with a low potential for adverse effects onweight andmetabolic
parameters, thus making it a promising candidate for maintenance
treatment.
We report here the results of a double-blind, 12 month follow-on
study that utilized a noninferiority design to evaluate the relapse preven-
tion efﬁcacy of lurasidone versus quetiapine XR (QXR) in subjects who
were responders to these treatments in an initial 6-week study. Use of a
noninferiority design permitted a rigorous comparison of lurasidone
with an established, well-tolerated agent, QXR, that is widely used, and
which has received regulatory approval in the US and Europe for the
maintenance treatment of schizophrenia based, in part, on demonstration
of relapse prevention efﬁcacy in a double-blind, randomized withdrawal
study (Peuskens et al., 2007). The primary noninferiority comparison
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lurasidone and QXR.
2. Methods
This was a double-blind, parallel-group study, utilizing a previously
randomized study population and a noninferiority design, to evaluate
the relapse prevention efﬁcacy of 12 months of ﬂexible dose treatment
with lurasidone (40–160 mg/d), compared with QXR (200–800 mg/d),
in outpatients with an acute exacerbation of chronic schizophreniawho
had recently completed 6 weeks of double-blind, placebo-controlled,
ﬁxed dose treatment with either lurasidone (80 mg/d or 160 mg/d)
or QXR (600 mg/d, included to conﬁrm assay sensitivity). The results
of the preceding short-term efﬁcacy study have been reported else-
where (Loebel et al., 2013).
The study protocol was approved by Independent Review Boards or
Ethics Committees associated with each study center, and all subjects
provided separatewritten informed consent for this 12 month continu-
ation study, whichwas conducted fromDecember 2008 to June 2011 at
58 centers in 6 countries. The current long-term continuation study, as
well as the preceding acute study phase was monitored by an indepen-
dent Data and Safety Monitoring Board.
The primary relapse prevention analysis population was deﬁned,
a priori, as all subjects who were randomized to either once-daily
lurasidone (80 mg or 160 mg) or QXR 600 mg in the initial 6 week
treatment study, and who met clinical response criteria on Day 42,
deﬁned as ≥20% reduction in PANSS total score from acute study
baseline and a CGI-S ≤ 4 at Day 42 (moderate-or-less illness
severity). The core phase placebo to continuation lurasidone
treatment group (PBO-LUR) was included in secondary efﬁcacy and
safety analyses. Study medication was taken once daily in the
evening with a meal or within 30 min after eating.
2.1. Assessments
Efﬁcacy was assessed using the PANSS total and subscale scores
(Kay et al., 1994; Marder et al., 1997), the Clinical Global Impression,
Severity scale (CGI-S; Guy, 1976), the Negative Symptom Assessment
Scale (NSA-16; Axelrod et al., 1993), and the Montgomery–Åsberg
Depression Rating Scale (MADRS; Montgomery and Asberg, 1979).
PANSS and CGI-S evaluations were performed at Baseline (Day 42 of
acute treatment), and at Months 3, 6, 9, and 12. The present study
also included an assessment of cognitive function using a computer-
ized cognitive battery (reported elsewhere; Harvey et al., 2012).
Safety evaluations included vital signs, laboratory tests, 12-lead ECG,
and adverse events. Extrapyramidal symptoms were assessed with the
Simpson–Angus Rating Scale (SAS; Simpson and Angus, 1970), the
Barnes Rating Scale for Drug-Induced Akathisia (BAS; Barnes, 1989),
and the Abnormal Involuntary Movement Scale (AIMS; Guy, 1976).
Daytime sleepiness was evaluated using the Epworth Sleepiness Scale
(Johns, 1991). Adherence was assessed by monthly counts of study
medication; subjects who varied by more than 25% from their pre-
scribed dose were considered noncompliant.
2.2. Statistical methods
The primary relapse analysis was a noninferiority comparison,
based on a Cox proportional-hazards model (Cox, 1972), of time to
relapse of psychotic symptoms in the subgroup of subjects who
were responders to acute treatment and who continued to receive
lurasidone (N=139) and quetiapine XR (N=79). Country was used
as a covariate in the analysis. Relapse of psychotic symptoms was
deﬁned as the earliest occurrence of any of the following 3 criteria:
(1) worsening of ≥30% in the PANSS total score from Day 42 of the
initial acute treatment study and a CGI-S ≥ 3; (2) re-hospitalization
for worsening of psychosis; or (3) emergence of suicidal ideation,homicidal ideation and/or risk of harm. Subjects were not unblinded
at the time any relapse or hospitalization occurred.
Lurasidone was to be declared non-inferior to QXR in preventing re-
lapse if the upper bound of the 2-sided 95% conﬁdence limit for the haz-
ard ratio of lurasidone versus QXR was no greater than a prespeciﬁed
noninferiority margin of 1.93 (Leucht et al., 2003; Piaggio et al., 2006).
Determination of this margin was based on a meta-analysis of relapse
prevention studies in schizophrenia with second generation antipsy-
chotics (SGAs) and placebo, which reported relapse rates as 19% and
49%, respectively, or a 30% difference between SGA and placebo (Leucht
et al., 2003). In order to preserve at least 50% of the relapse prevention ef-
fect of SGAs compared to placebo, a noninferiority (NI) difference of 15%
was selected and relapse rates of 35% for lurasidone and 20% for QXR
were assumed (Piaggio et al., 2006; Peuskens et al., 2007).
Analysis of change in PANSS total and subscores, CGI-S, MADRS, and
NSA-16 was made based on a mixed model for repeated measurement
(MMRM) analysis that included ﬁxed effects terms for treatment, visit
(as a categorical variable), center, Day 0 score in the initial acute treat-
ment study, and treatment-by-visit interaction (Liang and Zeger, 2000).
Remission rates during study treatment were assessed using the
Remission in Schizophrenia Working Group (RSWG) criteria for
symptomatic remission which require that a threshold of improve-
ment be maintained for at least 6 months (Andreasen et al., 2005).
3. Results
Of the 353 subjects who completed the initial 6 week double-blind
trial, 292 (83%) entered the current 12 month relapse prevention
study: 151 subjects continued on lurasidone, 85 subjects continued on
QXR, and 56 subjects treated with placebo in the initial trial were
started on lurasidone (PBO-LUR group; Table 1). Subjects entering the
initial 6 week study were hospitalized with an acute exacerbation of
schizophrenia, with amean PANSS total score at pre-treatment baseline
of approximately 97 (Table 1). For the full intent-to-treat population in
the core 6 week treatment study, signiﬁcant efﬁcacywas demonstrated
for both the lurasidone and QXR treatment groups when compared
with placebo on both the primary and key secondary efﬁcacy outcomes
(Loebel et al., 2013). At the completion of 6 weeks of treatment, the
mean improvement in the PANSS total score was similar in the treat-
ment groups that were continued on lurasidone and QXR (−30.0 vs.
−29.2; p = 0.593; MMRM); and the mean improvement in CGI-S
was also similar in the lurasidone and QXR treatment groups (−1.9
vs.−1.8; p = 0.259; MMRM). Fig. 1 summarizes patients' disposition
during the 12 month course of the study.
3.1. Dose
During 12 months of lurasidone treatment, 4/151 (2.6%) subjects re-
ceived a modal daily dose of 40 mg, 18/151 (11.9%) received a modal
daily dose of 80 mg, 87/151 (57.6%) received a modal daily dose of
120 mg, and 42/151 (27.8%) received a modal daily dose of 160 mg.
During 12 months of QXR treatment, 1/85 (1.2%) subject received a
modal daily dose of 200 mg, 9/85 (10.6%) received a modal daily dose
of 400 mg, 48/85 (56.5%) received a modal daily dose of 600 mg, and
27/85 (31.8%) received a modal daily dose of 800 mg.
3.1.1. Efﬁcacy
The Kaplan–Meier (KM) estimates of the probability of relapse at
12 months were 23.7% for the lurasidone group and 33.6% for the QXR
group (Fig. 2-A). Subjects in the lurasidone group had a lower risk of re-
lapse during 12 months of treatment comparedwith subjects in the QXR
group, with a hazard ratio [95% CI] of 0.728 [0.410, 1.295], indicating a
27.2% reduction in relapse risk (primary, a priori Cox proportional haz-
ards model analysis). Since the upper limit of the hazard ratio (1.295)
was smaller than the prespeciﬁed noninferiority margin (1.93), the
Table 1




XRb (N = 85)
Placebo–lurasidoneb
(N = 56)
N % N % N %
Male 108 72 52 61 35 63
Race
White 87 58 56 66 32 57
Black 22 15 13 15 8 14
Asian 35 23 12 14 16 29
Other 7 5 4 5 0 0
Ethnicity, Hispanic/Latino 11 7 7 8 5 9
Prior hospitalizations: ≥4 71 47 41 48 26 46
Mean SD Mean Mean Mean SD
Age, years 37.1 11.7 38.5 10.4 37.5 11.4
Age at onset of illness, years 25.8 8.6 24.9 8.2 26.1 9.3
Duration of illness, years 10.8 9.4 13.2 10.3 11.0 9.7
Duration of current episode, days 31.4 12.0 30.6 11.8 34.7 14.6
PANSS Total scorec
Acute baseline 97.7 10.3 97.9 10.6 96.4 10.6
12-month baseline 66.7 15.5 67.8 14.2 76.3 17.2
CGI-Severityc
Acute baseline 4.9 0.5 4.9 0.6 5.0 0.4
12-month baseline 3.0 0.7 3.1 0.8 3.7 0.8
MADRS total scorec
Acute baseline 12.0 8.1 12.8 8.8 11.1 6.6
12-month baseline 5.7 4.9 7.0 5.6 7.1 5.6
PANSS = Positive and Negative Syndrome Scale; CGI = Clinical Global Impressions scale; MADRS = Montgomery–Åsberg Depression Rating Scale.
a Data shown are for the safety population, except for PANSS total, CGI-Severity and MADRS scores, which are based on the intent-to-treat population.
b Lurasidone–lurasidone: treated with lurasidone in both the acute double-blind andmaintenance studies; placebo–lurasidone: treated with lurasidone in the acute double-blind
study, then switched to lurasidone in the maintenance study; quetiapine XR–quetiapine XR: treated with quetiapine XR in both the core double-blind and maintenance studies.
c Based on ITT population (lurasidone–lurasidone, n = 132; quetiapine XR–quetiapine-XR, n = 72; placebo–lurasidone, n = 52).
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this study.
The KM estimate of the probability of hospitalization at 12 months
was signiﬁcantly lower for lurasidone vs. QXR (9.8% vs. 23.1%; p b 0.05;
Fig. 2-B). Twelve months of treatment with lurasidone was associated
with a 56.7% reduction in the risk of hospitalization compared with
QXR (hazard ratio [95% CI], 0.433 [0.188, 0.995]; based on a post-hoc
Cox proportional hazards model). The rate of hospitalization amongFig. 1. Study ﬂow diagram and subject disposition during 12 months of double-blind (subjects who met a priori relapse criteria was signiﬁcantly higher for
QXR (61.9%) compared with lurasidone (34.5%; p b 0.05).
A sensitivity analysis was performed for all subjects who contin-
ued treatment with lurasidone (n = 151) or QXR (n = 85) in the
current study regardless of responder status. A lower probability
of relapse at 12 months for lurasidone vs. QXR (23.0% vs. 35.8%;
hazard ratio [95% CI] of 0.660 [0.381, 1.143] was found; Supplemen-
tal Fig. S1).DB) treatment with lurasidone or quetiapine XR in the relapse prevention study.
Fig. 2. Kaplan–Meier plots. A. Probability of not relapsing during 12 months of double-blind treatmentwith lurasidone (LUR–LUR) or quetiapine XR (QXR–QXR) during the relapse preven-
tion study. B. Probability of not being hospitalized during 12 months of double-blind treatment with lurasidone (LUR–LUR) or quetiapine XR (QXR–QXR) in the relapse prevention study.
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There was signiﬁcantly greater change in the PANSS total and posi-
tive subscale scores for lurasidone vs. QXR (Table 2; Supplemental Fig.
S2), however, endpoint improvement was similar for the PANSS nega-
tive subscale, NSA-16, and CGI-S scores (Table 2). Among subjects in
the PBO-LUR group, endpoint improvement in PANSS total and subscale
scores, CGI-S, andMADRSwas comparable to that observed for subjects
initially treated with lurasidone (Supplemental Table S1).
A signiﬁcantly higher proportion of subjects met full RSWG remis-
sion criteria (including the minimum 6-month duration criterion)
(Andreasen et al., 2005), in the lurasidone group compared with the
QXR group (61.9% vs. 46.3%; p b 0.05; LOCF endpoint analysis).
There was signiﬁcantly greater change in the MADRS, from pre-
treatment baseline for subjects who continued treatment with
lurasidone compared with subjects who continued treatment with
QXR (−6.0 vs. −3.8; p b 0.05; Supplemental Fig. S3), but not from
the baseline of the current 12 month study (Table 2).3.1.2.1. Safety. The effect of study treatment on safety parameters
(laboratory values, weight) is reported using an OC analysis of change
from pre-treatment baseline (Table 3).3.1.2.2. Body weight, BMI, and waist circumference. There were minimal
effects on mean body weight, BMI, and waist circumference in the
lurasidone and PBO-LUR groups (OC analysis of change from acute
study baseline; Table 3). Clinically signiﬁcant (≥7%) increase in
weight, from acute study baseline, was reported by a lower propor-
tion of subjects at Months 6 and 12 in the lurasidone group (13.6%
and 11.5%, respectively), and the PBO-LUR group (10.3% and 13.8%)
compared with the QXR group (27.5% and 15.2%; Table 3).
3.1.2.3. Metabolic parameters. As summarized in Table 3, 12 months of
treatment with lurasidone and QXR was associated with minimal ef-
fects on lipid parameters and measures of glycemic control, including
glucose, HbA1c, insulin, and HOMA-IR. At Month 6, treatment with
QXR was associated with an increase in total and LDL cholesterol,
and triglycerides, but minimal changes were observed among com-
pleters at Month 12.
3.1.2.4. Prolactin and other laboratory values. The median changes in
prolactin levels at Months 6 and 12 were similar among subjects in
the lurasidone, QXR, and PBO-LUR groups (Table 3). No clinically rel-
evant differences were noted for any other laboratory values when
comparing the lurasidone, QXR, and PBO-LUR groups.
Table 2






LS Mean SE LS Mean SE
PANSS
Total
Change from acute study baseline −34.6** 1.8 −25.7 2.6
Change from 12-month study baseline −5.0** 1.4 +1.7 2.1
Positive subscale
Change from acute study baseline −12.3** 0.5 −9.6 0.7
Change from 12-month study baseline −1.5** 0.4 +0.7 0.6
Negative subscale
Change from acute study baseline −7.2 0.4 −6.6 0.6
Change from 12-month study baseline −0.9 0.4 −0.8 0.5
CGI-S
Change from acute study baseline −1.9 0.1 −1.6 0.1
Change from 12-month study baseline 0.0 0.1 +0.2 0.1
NSA-16
Change from acute study baseline −14.7 0.8 −15.0 1.1
Change from 12-month study baseline −3.7 0.8 −4.3 1.1
MADRS
Change from acute study baseline −6.0* 0.6 −3.8 0.9
Change from 12-month study baseline +0.1 0.6 +1.3 0.8
*p b 0.05. **p b 0.01. ***p b 0.001.
PANSS: Positive and Negative Syndrome Scale; CGI-S: Clinical Global Impression, Severity Scale; MADRS: Montgomery–Asberg Depression Rating Scale; NSA-16: Negative Symptom Assess-
ment Scale; LS: least squares; acute baseline: prior to randomization in theprevious acute 6-weekdouble-blind study; estimates, standard errors (SE), andp-values are basedon amixedmodel
for repeatedmeasures (MMRM) of the change from acute/maintenance baseline score; the analysis used ﬁxed effects for pooled center, visit as a categorical variable, acute/maintenance base-
line score, treatment, and treatment by visit interaction, and assumed an unstructured covariance matrix. The ITT sample for secondary efﬁcacy analyses consisted of subjects who had both a
baseline and at least one post-baseline efﬁcacy assessment.
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occurred at some point during the overall course of the initial 6 week
and 12 month follow-on studies in 3/203 (1.5%) subjects in the com-
bined lurasidone group, and in 3/81 (3.7%) subjects in the QXR group;
orthostatic tachycardia occurred in 3/203 (1.5%) of the subjects in the
lurasidone group, and in 6/81 (7.4%) of the subjects in the QXR group.
There were no other clinically signiﬁcant treatment-emergent changes
in either of the lurasidone groups or the QXR group in vital signs or
physical examination.
3.1.2.6. ECG. There were no clinically signiﬁcant treatment-emergent
ECG abnormalities in the lurasidone, QXR, and PBO-LUR groups. The
mean increases in QTcF interval, from acute study baseline to Month
12, were 5.8 ms in the lurasidone group (n = 76), 8.7 ms in the
PBO-LUR group (n = 29), and 0.8 ms in the QXR group (n = 31). The
mean increases in QTcF interval, from acute study baseline to Month
12, based on an LOCF analysis, were 4.3 ms in the lurasidone group
(n = 122), 8.8 ms in the PBO-LUR group (n = 49), and 1.1 ms in the
QXR group (n = 65). No subjects in any of the 3 treatment groups ex-
perienced ≥60 ms increase in QTcF interval, or had a QTcF interval
>500 ms, at any time during 12 months of treatment in the current
study.
3.1.2.7. Extrapyramidal symptoms and akathisia. The proportions of
subjects reporting an extrapyramidal-related adverse event during
12 months of treatment in the current study were 11.9% in the
lurasidone group, 3.5% in the QXR group, and 21.4% in the PBO-LUR
group. The incidences of akathisia were 12.6% in the lurasidone group,
2.4% in the QXR group, and 10.7% in the PBO-LUR group. As summarized
in Supplemental Table S2, there were minimal changes in the BAS, SAS,
and AIMS during 12 months of study treatment. The proportions of sub-
jects who received an anticholinergic medication at any time during
12 months of treatment in the current study were 19.2% in the
lurasidone group, 5.9% in the QXR group, and 21.4% in the PBO-LUR
group. Beta-adrenoceptor blocking agentswere used by 4.6% of subjectsin the lurasidone group, 5.9% of subjects in the QXR group, and 5.4% of
subjects in the PBO-LUR group.
3.1.2.8. Adverse events. The proportions of subjects reporting at least
one adverse during 12 months of treatment in the current study were
64.2% for the lurasidone group, 62.5% for the PBO-LUR group, and
71.8% for the QXR group (Supplemental Table S3). The three most fre-
quent adverse events in the lurasidone group were akathisia (12.6%),
headache (10.6%), and insomnia (7.9%); and the three most frequent
events in the QXR group were worsening of schizophrenia (15.3%), in-
somnia (9.4%), and headache (9.4%). The majority of adverse events in
all treatment groups were rated as mild to moderate in intensity.
4. Discussion
We report here the results of a double-blind, long-term, follow-on
study comparing the efﬁcacy of ﬂexibly-dosed lurasidone and QXR for
the prevention of relapse in schizophrenia. A number of different
study designs have been utilized to assess the maintenance efﬁcacy
of antipsychotic treatment in patients with schizophrenia. To our
knowledge this is the ﬁrst study to incorporate all of the following
features: a double-blind, parallel group, continuation design, using
prespeciﬁed relapse criteria and a non-inferiority analysis. These de-
sign features provide a methodologically rigorous basis for the assess-
ment of the maintenance efﬁcacy of lurasidone in the treatment of
schizophrenia.
Lurasidone was found to be non-inferior to QXR in time-to-relapse,
with a numerically lower probability of relapse at 12 months in the
lurasidone group compared with the QXR group (23.7% vs. 33.6%;
log-rank p = 0.280). A sensitivity analysis involving all subjects treated
with lurasidone or QXR in the initial 6 week study (regardless of re-
sponder status) was consistent with the primary analysis: the probabil-
ity of relapse at 12 monthswas lower in the lurasidone group compared
with the QXR group (23.0% vs. 35.8%; log-rank p b 0.05).
Table 3
Safety parameters: change from acute study baseline to months 6 and 12 (observed case analysis).
Lurasidone–lurasidone Quetiapine XR–quetiapine XR Placebo–lurasidone
n n n
Weight, kg, mean (SD)
Baseline, acute study 151 72.7 (15.8) 85 72.4 (17.4) 56 73.9 (16.5)
Month 6 change 103 +1.3 (4.0) 51 +2.4 (6.3) 39 +0.4 (4.6)
Month 12 change 78 +0.7 (3.4) 33 +1.2 (4.6) 29 +0.3 (4.9)
≥7% increase in weight, n (%)
Month 6 change 103 14 (13.6) 51 14 (27.5) 39 4 (10.3)
Month 12 change 78 9 (11.5) 33 5 (15.2) 29 4 (13.8)
Body mass index, kg/m2, mean (SD)
Baseline, acute study 151 25.0 (4.5) 85 25.6 (4.9) 56 25.7 (4.9)
Month 6 change 103 +0.5 (1.4) 51 +0.8 (2.1) 39 +0.1 (1.6)
Month 12 change 78 +0.3 (1.2) 33 +0.5 (1.6) 29 +0.1 (1.7)
Waist circumference, cm, mean (SD)
Baseline, acute study 151 86.3 (13.2) 85 87.2 (14.4) 56 86.8 (12.9)
Month 6 change 103 +1.4 (5.0) 51 +1.2 (8.4) 39 +0.2 (6.7)
Month 12 change 78 +0.9 (3.8) 33 +0.6 (4.3) 29 +1.6 (5.7)
Total cholesterol, mg/dL, median
Baseline, acute study 151 184.0 85 187.0 56 183.5
Month 6 change score 102 −7.0 51 +6.0 39 −17.0
Month 12 change score 77 0.0 33 +4.0 28 −11.5
LDL cholesterol, mg/dL, median
Baseline, acute study 151 111.0 85 109.0 56 109.0
Month 6 change score 102 −1.5 51 +4.0 39 −8.0
Month 12 change score 77 −3.0 33 0.0 28 −5.0
HDL cholesterol, mg/dL, median
Baseline, acute study 151 44.0 85 42.0 56 42.0
Month 6 change score 102 0.0 51 0.0 39 −4.0
Month 12 change score 77 0.0 33 +4.0 28 −4.0
Triglycerides, mg/dL, median
Baseline, acute study 151 106.0 85 112.0 56 120.0
Month 6 change 102 0.0 51 +6.0 39 −15.0
Month 12 change 77 −18.0 33 −7.0 28 −17.5
Glucose, mg/dL, median
Baseline, acute study 151 92.0 85 91.0 56 92.5
Month 6 change 100 −0.5 50 +2.0 39 −4.0
Month 12 change 76 +1.0 33 +1.0 28 −2.5
HbA1c, %, mean
Baseline, acute study 151 5.5 85 5.5 56 5.4
Month 6 change 98 +0.1 46 +0.0 36 +0.1
Month 12 change 76 +0.2 33 +0.0 29 +0.1
Insulin, mU/L, median
Baseline, acute study 148 9.2 82 8.7 56 9.1
Month 6 change 98 −1.8 49 −2.0 39 −2.8
Month 12 change 76 −0.9 32 +1.2 28 +0.6
HOMA-IR, mean
Baseline, acute study 146 4.4 82 4.0 55 3.7
Month 6 change 95 −1.8 48 −1.4 39 −0.6
Month 12 change 75 −1.8 32 +0.2 28 −1.3
Prolactin, ng/mL, median
Baseline, acute study 151 7.9 85 8.7 56 9.4
Month 6 change 102 0.0 51 −1.3 39 +1.0
Month 12 change 77 +0.6 33 −0.7 28 +1.0
Month 6: 6 months post-baseline of relapse prevention study; Month 12: 12 months post-baseline of relapse prevention study.
HbA1c = glycosylated hemoglobin; HOMA-IR = homeostatic model assessment of insulin resistance (analyzed post hoc); LDL = low-density lipoprotein; HDL = high-density
lipoprotein.
100 A. Loebel et al. / Schizophrenia Research 147 (2013) 95–102For the population included in the primary analysis, the probability of
hospitalization at 12 months (one component of the prespeciﬁed com-
posite relapse risk deﬁnition) was lower for the lurasidone group
compared with the QXR group (9.8% vs. 23.1%; log-rank p b 0.05). In ad-
dition, the rate of hospitalization was higher among subjects who re-
lapsed and who were treated with QXR (61.9%) compared with
lurasidone (34.5%; p b 0.05). These results suggest that psychotic relapse
was not only more frequent, but may have been associated with greater
severity in patients treated with QXR. Since hospitalization accounts for
the largest share of the cost of schizophrenia (Ascher-Svanum et al.,
2010; Peng et al., 2011), reduction in risk of hospitalization is likely to
be associated with substantial cost savings. An analysis of the estimated
cost savings associated with lurasidone treatment in this study will be
reported separately.The major ﬁndings of the current study should be placed in the con-
text of previous relapse prevention trials. Two recent meta-analyses
have evaluated the relapse prevention efﬁcacy of antipsychotic drugs
during the longer-term treatment of schizophrenia. In a meta-analysis
of 65 placebo-controlled trials (Leucht et al., 2012), antipsychotic agents
were found to signiﬁcantly reduce relapse rates at 12 months when
compared with placebo (antipsychotics 27% vs. placebo 64%; risk ratio
[RR] 0.40). In a meta-analysis of 26 randomized trials comparing atypi-
cal and conventional antipsychotics (Kishimoto et al., 2011), atypicals
were found to signiﬁcantly reduce relapse rates at 12 months when
compared with conventional antipsychotics (atypicals, 31% vs. conven-
tionals, 37%). These meta-analyses underscore the substantial efﬁcacy
of antipsychotic agents inmaintaining improvement and preventing re-
lapse in patients with schizophrenia.
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with a relapse rate at one year (23.7%) that is comparable, or better
than, the rate reported in meta-analyses of randomized trials compar-
ing atypical (31%) and conventional antipsychotics (37%; Kishimoto et
al., 2011), and is comparable to the rate reported at one year for antipsy-
chotics in placebo-controlled trials (27%; Leucht et al., 2012). One ran-
domized, double-blind study is available that speciﬁcally evaluated
the relapse prevention efﬁcacy of QXR over a 6 month duration
(Peuskens et al., 2007). In that study, the relapse rate at 6 months was
14.3% for QXR, whichwas somewhat lower than the estimated rate (ap-
proximately 21%) observed at 6 months in the current 12 month trial
(Fig. 2-A). The lower relapse rate at 6 months in the study by
Peuskens et al. (2007) may be accounted for by differences in study de-
sign (4 month stabilization; randomized withdrawal design), and by
inclusion of a less severely ill patient sample.
The comparative effectiveness of lurasidone in the long-term treat-
ment of schizophrenia was also demonstrated on secondary measures
in the current study. Discontinuation due to insufﬁcient clinical re-
sponse was lower in the lurasidone group compared with the QXR
group (9.3% vs. 21.2%). Treatment with lurasidone was associated
with signiﬁcantly greater endpoint improvement versus QXR in the
PANSS total and positive subscale; but was similar on the PANSS nega-
tive subscale and on the NSA-16.
Remission rates, based on full RSWG criteria requiring sustained
improvement for at least 6 months (Andreasen et al., 2005), were
also higher for the lurasidone group compared with the QXR group
(61.9% vs. 46.3%; p b 0.05). The remission rate observed in the
lurasidone treatment group is notable as the study population had
experienced a recent acute exacerbation (mean PANSS total score
at acute study baseline, 97) of a highly chronic, recurrent illness
(mean duration > 10 years; approximately half of subjects with
≥4 prior hospitalizations), and had not experienced an extended,
post-acute period of stabilization prior to entering the current
study. Remission is an important treatment goal in schizophrenia be-
cause it is correlated with functional and occupational outcomes
(Bodén et al., 2009; Cassidy et al., 2010). The remission rate observed
for lurasidone in the current study is among the highest reported in
studies that utilize full RSWG criteria to deﬁne remission (Emsley
et al., 2011). The functional outcome implications of remission rate
ﬁndings in the current study warrant further investigation.
The consistency of the efﬁcacy advantage in favor of lurasidone in
the current study is in contrast to the results of the initial 6 week,
ﬁxed dose, double-blind trial, where improvement on lurasidone and
QXR was similar (Loebel et al., 2013). The reasons for emergence of an
efﬁcacy difference favoring lurasidone during this continuation study
are uncertain. The difference in relapse risk does not appear to be due
to a difference in tolerability between lurasidone andQXR, since discon-
tinuation due to adverse events was similar in this continuation study
(6.6% vs. 4.7%). The difference in relapse risk in favor of lurasidone
also does not appear to be due to inadequate dosing with QXR, since
the modal daily dose of QXR was either 600 mg or 800 mg in 88% of
subjects. The mean modal daily dose of QXR utilized in the current
study (637.6 mg)was similar to themeandose of 646 mgused in a pre-
vious QXR relapse prevention study (Peuskens et al., 2010). Further-
more, daily dosages of QXR above 600 mg have not been shown to be
associated with a signiﬁcant efﬁcacy advantage compared with a daily
dose of 600 mg (Zhornitsky et al., 2011).
The results of the current study suggest that 12 months of treatment
with lurasidone, in doses up to 160 mg/day, has a relatively lowpotential
for causing adverse weight and metabolic effects. Triglyceride levels
were reduced in the lurasidone group, while total and LDL cholesterol
levels were either unchanged or reduced. Long-term treatment with
lurasidone was also found to have no adverse effect on measures of gly-
cemic control, as indicated byminimal effects on glucose, HbA1c, insulin,
and HOMA-IR. These long-term data conﬁrm and extend the ﬁndings
obtained in short-term, ﬁxed dose lurasidone studies (Nakamura et al.,2009; Citrome, 2011; Meltzer et al., 2011) indicating that lurasidone
has a low propensity for adverse effects on weight, lipids and glucose
metabolism. With evidence suggesting that cardiovascular mortality
risk in schizophrenia may have increased since the introduction of atyp-
ical antipsychotics (Saha et al., 2007; Weinmann et al., 2009; Brown et
al., 2010), there is little doubt that additional metabolically neutral anti-
psychotic treatment options are needed, in addition to close attention to
physical healthmonitoring for patients receivingmaintenance treatment
(Meyer, 2010).
Treatment with QXR was associated with clinically signiﬁcant
increases in weight and metabolic parameters at 6 months, howev-
er, changes were minimal among the 39% of subjects who complet-
ed 12 months of treatment. The variation in weight and metabolic
outcomes observed for QXR at 6 and 12 months of treatment in
the current study may be attributable, in part, to relatively high at-
trition rates (61.2%) over 12 months of treatment with this agent.
Treatment with QXR was also associated with small increases at
12 months in glucose, insulin, and HOMA-IR, but no change in
HbA1c. These ﬁndings are consistent with changes in glycemic con-
trol reported in a previous long-term QXR study need reference
here.
Overall, 12 months of treatment with lurasidone and QXR was gen-
erally well-tolerated, with the majority of adverse events in the mild-
to-moderate severity range.Movement disorder-related adverse events
were reportedmore frequently by lurasidone compared to QXR-treated
subjects (11.9% vs.3.5%). The rates of parkinsonism (6.0%) and akathisia
(12.6%) for lurasidone in the current studywere consistentwithprevious
trials in subjects with schizophrenia (Latuda USPI, 2012).
This was the ﬁrst lurasidone long-term study to utilize evening
dosing of study medications. The relatively low incidence of adverse
events observed in both the preceding acute study (Loebel et al.,
2013), and this 12-month continuation study, suggests that this may
be an optimal dosing strategy for lurasidone.
Several potential study limitations should be noted. First, subjects
did not undergo a prespeciﬁed period of stabilization prior to entry
into the relapse prevention phase. Second, all subjects who complet-
ed the acute study were enrolled in the current 12 month relapse
prevention study, but were not re-randomized at the time of entry.
Re-randomization may have provided a more reliable method for lim-
iting potential selection bias for each study group in this study. How-
ever, the similarity of baseline clinical and demographic variables in
the core study and the current study, and the similarity in results
for the primary analysis and a sensitivity analysis that included all
subjects (regardless of responder status), suggest that selection bias
may have been minimal. Third, the current study did not include a
placebo control, which was judged to be ethically problematic in a
12 month trial in chronic schizophrenia.
In conclusion, this double-blind, active comparator-controlled,
12-month, ﬂexible-dose study in patients with schizophrenia, dem-
onstrated noninferiority to QXR for lurasidone in relapse prevention.
In addition, 12 months of treatment with lurasidone was associated
with a relatively low probability of relapse and hospitalization, and
a relatively high remission rate. This study also supports lurasidone's
low potential for long-term adverse effects on weight and other indi-
ces of metabolic function. This study also suggests that long-term
noninferiority studies using an active comparator are feasible in pa-
tients with schizophrenia, and have the potential to show clinical dif-
ferentiation among antipsychotic agents.Role of funding source
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